Effect of Rta protein of Epstein-Barr virus on the cell cycle in HeLa cells

Guo, Qingwei; Sun, Xiao-bai; Yuan, Changjin; Zhou, Huijuan; Li, Yanmei; Gao, Jie; Jiang, Guosheng

doi:10.4149/av_2011_04_311

Cited by 5 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EBV is also known to cause genomic instability which can occur when EBV switches between its lytic and latent phases. These phases are heavily influenced by the BZLF1 gene which arrests cell cycle development, and the BRLF1 gene which can cause the cell to inappropriately reenter the S phase causing problems in chromosomal segregation [13,14]. EBV, like many cancer-causing agents, has in-built mechanisms to evade the immune system which stymies the physiological response to anti-tumorigenesis.…”

Section: Epstein-barr Virus and Nasopharyngeal Carcinomamentioning

confidence: 99%

The Association of Epstein-Barr Virus With Cancer

Patel¹,

Alghareeb²,

Hussain³

et al. 2022

Cureus

View full text Add to dashboard Cite

Epstein-Barr virus (EBV) is classified as a herpesvirus and is known for being one of the few viruses that can lead to the development of cancer. This study has gathered several studies to provide evidence as to this association as well as some of the mechanisms specific to EBV that allow this to happen. The development of EBV into cancer as well as the proteins involved in this oncogenesis play a crucial role in understanding this problem as well as creating a solution for mitigating this disease process in the future. This study summarized three of the most common malignancies caused by EBV in order to consolidate information about each of them. Additional emphasis was placed on finding which EBV serum markers were seen to be most indicative of prognosis and likelihood of developing malignancy. Higher serum EBV viral DNA loads were seen to be a useful indicator in assessing the risk of various cancers and should be studied further in relation to cancers that were not mentioned in this review.

show abstract

Section: Epstein-barr Virus and Nasopharyngeal Carcinomamentioning

confidence: 99%

The Association of Epstein-Barr Virus With Cancer

Patel¹,

Alghareeb²,

Hussain³

et al. 2022

Cureus

View full text Add to dashboard Cite

show abstract

“…It was reported that the EBV lytic protein BZLF1 arrested cells in G0/G1 [ 27 ], G1/S [ 28 ] and G2/M [ 29 ]. It has been reported that BRLF1-expressing cells reenters S phase [ 30 ]. Our previous studies demonstrated that BRLF1 has ability to interfere with cells at the G1/S transition and induces a cellular senescence [ 31 , 32 ].…”

Section: Introductionmentioning

confidence: 99%

Epstein-Barr virus BRLF1 induces genomic instability and progressive malignancy in nasopharyngeal carcinoma cells

Huang

Cheng

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Nasopharyngeal carcinoma (NPC) is a serious health problem in China and Southeast Asia. Relapse is the major cause of mortality, but mechanisms of relapse are mysterious. Epstein–Barr virus (EBV) reactivation and host genomic instability (GI) have correlated with NPC development. Previously, we reported that lytic early genes DNase and BALF3 induce genetic alterations and progressive malignancy in NPC cells, implying lytic proteins may be required for NPC relapse. In this study, we show that immediate early gene BRLF1 induces chromosome mis-segregation and genomic instability in the NPC cells. Similar phenomenon was also demonstrated in 293 and zebrafish embryonic cells. BRLF1 nuclear localization signal (NLS) mutant still induced genomic instability and inhibitor experiments revealed that BRLF1 interferes with chromosome segregation and induces genomic instability by activating Erk signaling. Furthermore, the chromosome aberrations and tumorigenic features of NPC cells were significantly increased with the rounds of BRLF1 expression, and these cells developed into larger tumor nodules in mice. Therefore, BRLF1 may be the important factor contributing to NPC relapse and targeting BRLF1 may benefit patients.

show abstract